NCT00071084View on ClinicalTrials.gov

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 27, 2003

Primary Completion Date

June 29, 2004

Study Completion Date

June 29, 2004

Conditions
Cutaneous T-Cell Lymphoma
Interventions
DRUG

HuMax-CD4

HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 16 weeks.

DRUG

HuMax-CD4

HuMax-CD4 980 mg was administered as a SC infusion OD up to 16 weeks.

Trial Locations (5)

94305-5152

Stanford University Med Ctr., Dept of Dermatology, Stanford

77030-4009

University of Texas, M.D. Anderson Cancer Center, Houston

Unknown

Münster

Stockholm

London

Sponsors

Lead Sponsor

Genmab
All Listed Sponsors
lead

Genmab

INDUSTRY

NCT00071084 - Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. | Biotech Hunter | Biotech Hunter